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Background: Remodelling in COPD has at least two dimensions: small airway wall thickening and destruction of
alveolar walls. Recent studies indicate that there is some similarity between alveolar and small airway wall matrix
remodelling. The aim of this study was to characterise and assess similarities in alveolar and small airway wall matrix
remodelling, and TGF-β signalling in COPD patients of different GOLD stages.
Methods: Lung tissue sections of 14 smoking controls, 16 GOLD II and 19 GOLD IV patients were included and
stained for elastin and collagens as well as hyaluronan, a glycosaminoglycan matrix component and pSMAD2.
Results: Elastin was significantly decreased in COPD patients not only in alveolar, but also in small airway walls.
Interestingly, both collagen and hyaluronan were increased in alveolar as well as small airway walls. The matrix
changes were highly comparable between GOLD stages, with collagen content in the alveolar wall increasing
further in GOLD IV. A calculated remodelling index, defined as elastin divided over collagen and hyaluronan, was
decreased significantly in GOLD II and further lowered in GOLD IV patients, suggesting that matrix component
alterations are involved in progressive airflow limitation. Interestingly, there was a positive correlation present
between the alveolar and small airway wall stainings of the matrix components, as well as for pSMAD2. No
differences in pSMAD2 staining between controls and COPD patients were found.
Conclusions: In conclusion, remodelling in the alveolar and small airway wall in COPD is markedly similar and
already present in moderate COPD. Notably, alveolar collagen and a remodelling index relate to lung function.Background
Chronic obstructive pulmonary disease (COPD), currently
the fourth leading cause of death, is characterised by re-
duction in expiratory airflow that is not completely revers-
ible [1]. The major risk factor of COPD is cigarette
smoking. Lung remodelling in COPD is marked by several
characteristics, like accumulation of mucous secretions
and bronchiolar fibrosis in the proximal airways and re-
modelling of small airway and alveolar walls. Small air-
ways are most important in the reduction of FEV1.
Importantly, remodelling of small airways is mainly associ-
ated with excess matrix deposition, whereas the neigh-
bouring alveoli are hallmarked by destruction. Given these* Correspondence: n.reynaert@maastrichtuniversity.nl
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reproduction in any medium, provided the oropposing remodelling processes, small airways and alveoli
are mainly studied separately.
Small airway remodelling affects the transition zones be-
tween airway and alveolar spaces with both air-conducting
and gas-exchange functions. Small airways are usually de-
fined as < 2 mm in internal diameter without cartilage.
They have the characteristically folded respiratory epithe-
lium surrounded by a smooth muscle layer and supported
by connective tissue without glands. Their thin walls offer
little resistance to laminar airflow in healthy subjects [2].
Small airways obstruction in COPD is associated with air-
way wall thickening by remodelling related to tissue repair
and accumulation of inflammatory exudates [3]. Evidence
suggests that small airway remodelling arises as a result of
epithelial abnormalities or from smooth muscle hyper-
trophy/hyperplasia [4-6]. Most studies show airway wall
thickening based on image analysis. Studies into the mo-
lecular changes in extracellular matrix associated with
small airway remodelling in COPD and mechanismsl Ltd. This is an Open Access article distributed under the terms of the Creative
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and glycosaminoglycan deposition [7,8]. Also, thickening
of the subepithelial layer of the airway wall, by increased
expression of collagen I and III precursors was shown in
airway wall biopsies of COPD patients, however very se-
vere patients showed decreased precursor levels and a
changed collagen I to collagen III ratio [9,10].
The main lesion in alveolar wall remodelling is emphy-
sema, defined as “a condition of the lung characterised
by abnormal, permanent enlargement of the airspaces
distal to terminal bronchioles, accompanied by destruc-
tion of their walls and without obvious fibrosis” [11]. An
imbalance between proteinases and their inhibitors is
thought to account for the morphological changes [12].
Recently, studies have implicated that there might be
more similarity between small airway and alveolar remod-
elling as previously thought. For instance, elastic fibres not
only decreased in the alveolar but also in small airway
walls in COPD [13]. Comparable extracellular matrix
composition [14] and decreased levels of αSMA positive
cells [15] in were found in parenchyma, small and large
airways of mild to moderate COPD patients. Furthermore,
fragmentation of the reticular basement membrane in
COPD was shown as an increased number of clefts in
small airways [16]. In addition, the number of small air-
ways was decreased in patients with COPD [17], which in-
dicates emphysema-like destruction of the small airways.
On the other hand some studies suggest that alveolar
septae show signs of fibrosis, by accumulation or in-
creased production of collagen [18] and proteoglycans
[19,20]. The glycosaminoglycan hyaluronan, involved in
maintaining the assembly of collagen fibrils and water
homeostasis plays an important role in COPD. We previ-
ously demonstrated higher levels of hyaluronan, in both
alveolar and airway walls of cigarette smoke exposed mice
[21], and in sputum of COPD patients [22]. So far, none of
these previously mentioned studies examined matrix re-
modelling simultaneously in different compartments of
the lung and in both moderate and severe COPD patients.
TGF-β is an important regulator of extracellular matrix
deposition, as it controls expression of components of the
extracellular matrix network and of protease inhibitors.
These combined anabolic and anti-catabolic effects make
it a key growth factor in the development of tissue fibrosis.
The main stimulatory signalling pathway involves associ-
ation of pSmad2 and pSmad3, which in concert with
Smad4 leads to activation of gene transcription of some
main extracellular matrix components including collagens.
To characterise matrix remodelling and assess the role
of TGF-β signalling in the distal lung, we examined
small airway and remaining alveolar wall extracellular
matrix content, phosphorylation of SMAD2 and their
interrelation within subjects. To this end, area fractions
of the major lung extracellular matrix componentselastin, collagen and hyaluronan, and pSMAD2 were
examined in small airway and alveolar walls. Further-
more the association between remodelling and lung
function was assessed.
Methods
Study subjects and tissue collection
Lung tissue was obtained from the upper lobe subpleural
area of 19 GOLD IV patients who underwent lung volume
reduction surgery. From both 14 control subjects and 16
GOLD II patients, who underwent resection for a solitary
peripheral tumour, tumour-free lung tissue in the sub-
pleural area at appropriate distance from the tumour was
taken. All lung tissue was obtained at University hospital
Maastricht, the Netherlands, and tissue with a cross-
sectional surface of approximately 2 cm2 was collected.
Signs of a respiratory tract infection during 4 weeks pre-
ceding the study and a history of respiratory diseases,
other than lung cancer were considered exclusion criteria.
The number of pack years and the smoking status were
recorded. People who stopped smoking at least 1 year
prior to recruitment was considered an ex- smoker. All
subjects had smoked at least 10 pack-years.
Lung function was determined by spirometry, and
post-bronchodilator forced expiratory volume in 1 sec
(FEV1) and forced vital capacity (FVC) were calculated
from the flow-volume curve, and FEV1/FVC was calcu-
lated. Patients with FEV1/FVC < 0.70 and FEV1 between
50 and 80% were considered GOLD II, having FEV1
lower than 30% of normal were considered GOLD IV.
All patients were prescribed combination therapy of in-
haled corticosteroids and long-acting β2-agonists, tiotro-
pium/ipratropiumbromide and salbutamol, on demand.
This study was conducted in compliance with the
Helsinki Declaration. Lung tissue was obtained from the
Maastricht Pathology Tissue Collection (MPTC). Collec-
tion, storage and use of tissue and patient data were per-
formed in agreement with the “Code for Proper
Secondary Use of Human Tissue in the Netherlands”.
The scientific board of the MPTC approved the use of
materials for this study under MPTC 2009–22.
Staining
Four μm paraffin sections were cut from formalin fixed
and paraffin embedded tissue.
For elastin staining, slides were incubated for 20 mi-
nutes in Weigert’s resorcin-fuchsin (Chroma, Muenster,
Germany) at 60–70°C and counterstained in a 0.25% tar-
trazine (Chroma) in 0.25% acetic acid solution.
Collagen was stained by incubation for 90 minutes in
0.1% Picro Sirius Red, known to stain collagen I as well
as II and III, in saturated aqueous picric acid, pH = 1.5
(Klinipath, Duiven, the Netherlands). Thereafter, sections
were counterstained with haematoxylin.
Table 1 Clinical characteristics of study subjects
Control GOLD II GOLD IV
Number 14 16 19
Age (years) 63 ± 6 65 ± 7 61 ± 7
Sex (M/F) 9/5 13/3 *$ 12/7
Pack-years § 25 ± 16 46 ± 14* 47 ± 29*
Smoking status (current/ex) 4/9 11/5 0/19*^
FEV1 (%predicted) 107 ± 15 67 ± 9* 22 ± 4*^
FEV1/FVC 80 ± 6 59 ± 9* 26 ± 7*^
Tlco (% predicted) # 95 ± 16 77 ± 18* 35 ± 15*^
Data are displayed as mean ± SD or ratio, * means p < 0.05 compared to
controls, $ means significantly different compared GOLD IV. ^ means
significant compared to GOLD II. § Values from 3 controls, 4 COPD GOLD II
and 2 GOLD IV patients are missing. # Values from 2 controls, 1 COPD GOLD II
and 9 GOLD IV patients are missing. FEV1 (%predicted) and FEV1/FVC are
measured post-broncholdilation.
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labelled hyaluronan binding protein was used (Calbiochem,
Darmstadt, Germany) for 1 h. VECTASTAIN ABCom-
plex/AP system (Vector, Burlingame, CA) was used for en-
zymatic reactivity and visualized with Vector Blue alkaline
phosphatase substrate kit (Vector). Sections were counter-
stained with Nuclear fast red (Vector).
Phosphorylated SMAD2 was detected using a rabbit
monoclonal Ab against human pSMAD2 (#3108, Cell Sig-
nalling Technology). After application of biotin-conjugated
swine anti-rabbit IgG Ab (E-0431, DakoCytomation, Glostrup,
Denmark) and alkaline phosphatase-labeled avidin–biotin
complex (Vector), enzymatic reactivity was visualized using
the Vector Blue Substrate Kit (Vector). Sections were coun-
terstained with Nuclear Fast Red (Vector), mounted and
pSMAD2 was semi-quantitatively scored by two blinded in-
dependent observers. Repeatability of the scoring was tested
using the kappa coefficient which resulted in a value of κ =
0.79 which means a substantial agreement.
Quantification of matrix
Sections were scanned using a .slide light microscopy
slide scanner at 100 ×magnification (Olympus, Hamburg,
Germany) and analysed entirely using Leica QWin Pro
version3.5.1 software (Leica Microsystems, Cambridge,
United Kingdom) by a blinded observer. Per patient, 1
section of approximately 2 cm2 tissue, was divided in ap-
proximately 70 pictures, which were all analysed.
Alveolar staining was determined as percentage of
stained area to total alveolar tissue area present on the
slide. Therefore, first the total amount of tissue stained was
detected followed by exclusion of blood vessels and air-
ways. Thereafter, stained areas were selected and percent-
age of staining in the alveolar tissue was calculated by the
software. Suitable small airways, defined as smaller than
2 mm diameter and cut in cross-sections by a ratio of max-
imal to minimal internal diameter < 2.0, were selected.
From 14 controls, 13 GOLD II and 16 GOLD IV patients
2–4 airways per subject with a total of 111 airways were
measured for which the amount was not significantly dif-
ferent between the study groups. Staining was calculated as
percentage of stained area to total airway wall area. Airway
wall thickness was measured from the lumen to the outer
margin of the adventitia and calculated as mean wall width
by the software. Staining intensity was validated using a
pilot which contained five patients per group. All stainings
were checked by a pathologist, who confirmed the quanti-
fication results as generated by the researcher as well.
An elastin to collagen-hyaluronan index was calculated
to provide an estimation of ECM remodelling in terms
of elastin, collagen and hyaluronan in COPD. This index,
which was previously used in the lung [23], was adapted
and defined as: [Elastin-(Collagen + Hyaluronan)]/[Elastin +
(Collagen + Hyaluronan)] [23,24].Statistics
Results are displayed as mean ± SD. All data were nor-
mally distributed. Basic characteristics were analysed
using ANOVA or Chi Square. Stainings were analysed
using ANCOVA using age, sex, pack years and smoking
status as covariates. Bonferoni correction was used for
post-hoc analysis. Correlations were analysed by Pearson
correlations (SPSS version 19.0, SPSS Inc., Chicago, IL).
A p-value < 0.05 was considered significant.Results
Subject characteristics
The clinical characteristics of the study subjects are
summarized in Table 1. Controls and COPD patients
were matched for age, but the ratio of current to ex-
smokers differed significantly. Small airway wall width
tended to be increased in GOLD II (23.9 ± 6.8) and
GOLD IV (23.9 ± 9.9) compared to controls (19.8 ± 6.5);
however this was not significant (p = 0.12).Decreased elastin in alveolar and small airway walls of
COPD patients
Elastin is visible as dark purple strands (indicated by arrows)
and is notable in alveolar walls, small airway walls around
the epithelium and around blood vessels. We examined the
amount of elastin in alveolar (Figure 1A-C) and small airway
walls (Figure 1D-F) quantitatively (Figure 1G-H). As ex-
pected, the percentage of elastin in the alveolar walls was
significantly reduced in GOLD II and GOLD IV. Inter-
estingly, elastin was also decreased in the small airway
walls of both GOLD II and GOLD IV. However, no dif-
ference was observed between GOLD II and GOLD IV
patients for alveolar or small airway walls. There was a
significant correlation between alveolar and small air-
way wall elastin values (Table 2).
Figure 1 Decreased elastin in alveolar and small airway walls of COPD patients. Photomicrographs of elastin in alveolar walls of one
representative control subject (A), GOLD II patient (B), GOLD IV patient (C) and small airway walls of a control (D), a GOLD II patient
(E) and a GOLD IV patient (F). Quantitative measured elastin content in alveolar walls (G) and small airway walls (H). Data were analysed using
ANCOVA and results are expressed as means + SD; *P < 0.05 compared to control.
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small airway walls
Deposition of collagens (which could be either colla-
gen I, II and/or III) indicated by arrows was observed
in the pleura, perivascular, peribronchiolar in the basalTable 2 Correlations between alveolar matrix and small
airway matrix in the whole study group
R p
Elastin 0.558 < 0.001
Collagen 0.612 < 0.001
Hyaluronan 0.523 < 0.001
Remodelling index 0.830 < 0.001
pSMAD2 0.656 < 0.001
Data were analysed using Pearson correlations.membrane and connective tissue and in the alveolar
walls (Figure 2A-F). Interestingly, in the alveolar wall
collagen increased in GOLD II patients, which further
progressed in GOLD IV (Figure 2G). As expected, it
is shown that there is excess collagen deposition in
the small airway walls of GOLD II and GOLD IV pa-
tients compared to controls; however no significant
difference between GOLD stages was found (Figure 2H).
In addition a significant correlation between alveolar and
small airway collagen deposition was observed (Table 2).Increased hyaluronan in both alveolar and small airway
walls of COPD patients
Histochemical localization of hyaluronan was seen in the
alveolar walls affiliated to capillaries; more prominent
staining was observed in small airway walls and blood
Figure 2 Deposition of collagen in the alveolar walls in addition to small airway walls. Photomicrographs of collagen in alveolar walls of
one representative control subject (A), GOLD II patient (B), GOLD IV patient (C) and small airway walls of a control (D), a GOLD II patient (E) and
a GOLD IV patient (F). Quantitative measured collagen content in alveolar walls (G) and small airway walls (H). Data were analysed using
ANCOVA and results are expressed as means + SD; *P < 0.05 compared to control, **P < 0.05 compared to control and GOLD II.
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able to the localization of collagen (Figure 3A-F). Quan-
titatively enhanced hyaluronan was shown in alveolar
(Figure 3G) and small airway walls (Figure 3H) of GOLD
II and GOLD IV patients. No differences were found be-
tween GOLD II and GOLD IV patients. Again, a signifi-
cant correlation between alveolar and small airway
hyaluronan deposition was observed (Table 2).
Elastin to collagen-hyaluronan index is decreased in
COPD patients and correlates with lung function
parameters
Next the relationship between individual matrix com-
pounds and FEV1 was shown to be significant (Table 3).
Correlations were present for all matrix components in al-
veolar and small airway walls with FEV1. However, in the
COPD patients group alone, no significant correlationswere found with exception of the inverse relation between
alveolar collagen and FEV1.
An elastin-to-collagen-hyaluronan index was calcu-
lated to provide an estimation of the extent of ECM re-
modelling in COPD. Figure 4 shows that the index is
lower in both GOLD II and GOLD IV patients than in
controls. Furthermore, this index in contrast to the indi-
vidual matrix components was significantly different be-
tween GOLD II and GOLD IV patients for both alveolar
and small airway walls. Importantly, the remodelling
index correlated with FEV1 as well as FEV1/FVC in
COPD (Figure 5).
Correlation between alveolar and small airway wall
pSMAD2, despite absence of a relationship with COPD
To assess if the described remodelling is associated with
increased TGF-β signalling pSMAD2 was assessed by
Figure 3 Increased hyaluronan in both alveolar and small airway walls of COPD patients. Photomicrographs of hyaluronan in alveolar walls
of one representative control subject (A), GOLD II patient (B), GOLD IV patient (C) and small airway walls of a control (D), a GOLD II patient
(E) and a GOLD IV patient (F). Quantitative measured hyaluronan content in alveolar walls (G) and small airway walls (H). Data were analysed
using ANCOVA and results are expressed as means + SD; *P < 0.05 compared to control.
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out the lung, it was positive in alveolar macrophages and
it was also observed associated with blood vessels, namely
in the endothelial layer, in the smooth muscle cells of the
media and in fibroblasts in the adventitia. For this studyTable 3 Correlations between matrix and FEV1
Whole study group n
R
Elastin alveolar 0.734
Elastin small airway 0.599
Collagen alveolar −0.757
Collagen small airway −0.694
Hyaluronan alveolar −0.656
Hyaluronan small airway −0.434
Data were analysed using Pearson correlations.we focused on the staining which was observed in bron-
chial epithelium and its submucosa, as well as in fibro-
blasts, endothelial and type II epithelial cells in alveolar
walls (Figure 6A-B). No difference was seen between con-
trols and COPD patients in both small airway and alveolar= 49 COPD patients n = 35
p R P
< 0.001 0.107 0.553
< 0.001 0.318 0.106
< 0.001 −0.511 0.003
< 0.001 −0.219 0.262
< 0.001 −0.232 0.201
< 0.001 −0.194 0.333
Figure 4 Elastin to collagen-hyaluronan index is decreased in COPD patients. Elastin to Collagen-Hyaluronan index of controls, GOLD II and
GOLD IV patients in alveolar walls (A) and small airway walls (B). Data were analysed using ANCOVA and results are expressed as means + SD;
*P < 0.05 compared to control, **P < 0.05 compared to control and GOLD II.
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between alveolar and small airway pSMAD2 staining was
found (Table 2).
Discussion and conclusion
This study was performed to compare matrix content in
the distal lung of GOLD II patients, GOLD IV patients
and controls. The data obtained show marked similar-
ities in elastin, collagen and hyaluronan content changes
between the alveolar and small airway compartment. Re-
markably, only alveolar wall collagen was increased fur-
ther in highly emphysematous patients compared to
patients with moderate COPD and negatively correlated
with lung function. All other matrix alterations were in-
dependent of lung function.This study showed decreased elastin not only in alveolar
but also in small airway walls of COPD patients. These re-
sults are in contrast with a study in severe GOLD IV pa-
tients showing increased elastic fiber density in alveolar
walls [25]. This discrepancy could be caused by difference
in control groups between these studies, which in our case
were matched for age and smoking behaviour to the pa-
tient groups. In addition the data presented in this study
showed a positive correlation of elastin content with lung
function parameters using the whole study group. In
COPD patients alone no significant correlations were de-
termined. Previously, a study showed comparable correla-
tions with lung function parameters, in the whole group
including controls [13]. Combined with the lack of differ-
ence between GOLD II and GOLD IV patients, this
Figure 5 Elastin to collagen-hyaluronan index correlates with lung function parameters. Correlation in GOLD II and GOLD IV patients
between alveolar elastin to collagen-hyaluronan index and FEV1 (A), FEV1/FVC (B) and between small airway elastin to collagen-hyaluronan index
and FEV1 (C), FEV1/FVC (D). Data were analysed using Pearson correlation.
Figure 6 Correlation between alveolar and small airway wall pSMAD2, despite absence of a relationship with COPD. Photomicrographs
of pSMAD2 staining in blue of one representative control subject (A) and a COPD patient (B). Semi- quantitative scored pSMAD2 staining in
alveolar walls (C) and small airway walls (D). Data were analysed using ANCOVA and results are expressed as means + SD.
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likely a marker of disease, then of severity. A possible
underlying mechanism for the decreased elastin content
in the small airway wall is the increased number of
neutrophils [26], especially neutrophil elastase [27]. In
addition to loss of elastin, the number of small airways
was reduced in mild and severe emphysematous patients
[17]. The question remains whether the loss of elastin can
lead to collapse or disappearance of small airways.
Deposition of collagen and hyaluronan was increased
in small airway walls of COPD patients. This is an im-
portant finding as a number of studies showed small air-
way wall fibrosis, but there has been less research on the
matrix composition. It was shown that there is an in-
crease of collagen I and III precursors in the small air-
ways of GOLD II patients; whereas in GOLD IV patients
these precursors decreased [10], which can explain the
lack of progression of collagen in the small airways as
our data indicate. The current study shows elevated hya-
luronan content in in addition to collagen. Within the
lung collagen and elastin fibers are embedded in a hy-
drated gel of which glycosaminoglycans are the major
constituents. The composition of the matrix and the
fiber to gel ratio changes during maturation and disease
state [28]. Hyaluronan is the major glycosaminoglycan in
lung tissue and has diverse functions in lung homeosta-
sis and pulmonary disease. We previously showed that
hyaluronan was increased in sputum of COPD patients
[22]. Furthermore in cigarette smoke exposed mice there
was an increase in hyaluronan deposition in the small
airway wall after 4 weeks of exposure, which also was
not progressive in the 6 month exposure model of em-
physema [21].
Increased collagen and hyaluronan deposition in the
alveolar wall indicates that besides airway fibrosis there
are fibrotic matrix changes in the alveolar walls which
are also present in the remaining walls in severely
obstructed patients with advanced emphysema. This is
in line with previous research showing thickened alveo-
lar walls in COPD patients and a decreased elastin-to-
collagen index [23].
In this study two different disease phenotypes were
analysed, a GOLD IV group with advanced emphysema
and a moderately obstructed GOLD II group. We ob-
served no difference between these groups for the indi-
vidual matrix components, showing that changes in
matrix composition even occur in patients with moder-
ate airflow limitation. Only collagen in alveolar walls was
further increased in severely emphysematous patients. In
addition, collagen area fraction in the alveolar walls was
the only measure which correlated with TLCO within
the COPD group (R = −0.493, p = 0.02). This indicates
that next to destruction of alveolar walls, increased colla-
gen content in remaining walls contributes to reduction ofgas transfer. Unfortunately, correction for the amount of
alveolar tissue left in these patients was impossible. In an
elastase model it was shown that decreased elastin caused
increased alveolar collagen without inflammation. Fur-
thermore, it appears that remodelled collagen fibres are
weaker and break under the influence of mechanical stress
[29]. The mechanism underlying remodelling of elastin
and collagen, including subtyping composition and ultra-
structure, should be investigated to support their involve-
ment in emphysema development.
In addition, a significantly decreased remodelling index
in COPD patients was found. This index was also signifi-
cantly different for both small airway and alveolar walls of
COPD patients versus controls, in line with individual
matrix components. More interestingly there was a signifi-
cant difference in the remodelling index between GOLD
II and GOLD IV patients which positively correlated with
FEV1 and FEV1/FVC in the patient group. Although the
distribution was high, possibly due to the heterogeneous
GOLD II population, the correlations were strong and sig-
nificant. The individual matrix components on the other
hand did not differ significantly between GOLD stages
and did not correlate with lung function, indicating that
although the individual components are markers of dis-
ease, even in early stages, it is the combination of matrix
component alterations that is related to progressive air-
flow limitation.
The amount of pSMAD2 staining in alveolar and small
airway walls was not different between controls and
COPD patients. Literature on the role of TGF-β in
COPD is conflicting; some studies found increased ex-
pression of TGF-β in bronchial and alveolar epithelial
cells [30,31] whereas others observed no differences in
TGF-β levels in sputum, BALF and bronchial epithelial
cells by immunostaining [32-36]. The lack of difference
in pSMAD2 staining is in line with these latter publica-
tions [35]. In the smoking mouse model of COPD there
is evidence for increased TGF-β expression and SMAD
signaling [37]. Furthermore increased levels in TGF-β
expression were shown between never and current
smokers [32] while no difference between smokers and
COPD patients was present. In this study using smoking
controls, no differences were found in relation to the
disease. An effect of smoking per se cannot be excluded
given the lack of a never smoking control group.
The observed correlation between alveolar and small
airway wall matrix components invalidates previous
thoughts that alveolar and small airway remodelling are
two distinct processes which is in concert with some re-
cent publications [13,16,17]. The finding that elastin is
decreased in both alveolar and small airway walls and
that collagen and hyaluronan are increased in both com-
partments provides evidences that there are similar
matrix adaptations occurring simultaneously in alveoli
Eurlings et al. BMC Pulmonary Medicine 2014, 14:90 Page 10 of 11
http://www.biomedcentral.com/1471-2466/14/90and small airways. Furthermore, a positive correlation
was found in pSMAD2 staining between alveolar and
small airway walls, indicating that not only remodelling
in the small airways and alveolar walls can be seen as
one unit but that also TGF-β signalling as shown by
pSMAD2 is similar. The current study indicates that re-
modelling and TGF-β signalling in the alveolar and small
airway wall in COPD are markedly similar and that re-
modelling is already present in moderate COPD. Not-
ably, alveolar collagen and a remodelling index relate to
progressive airflow limitation.
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